Lincoln Capital is the new Socious. IMO they have been dumping some of their .08 shares, in small lots, to bring down the pps. At around .04 they will call a bottom, buy a ton of shares, run in back to .06, rinse and repeat. This is not shorting, and is not prohibited in their written agreement with GR. This is one way vulture capitalists make a living, or early-stage biotechs that are not yet ready for prime time. Up front and on paper, it sounds like solid financing (though it's better that the terrible financing that GR and Caldwell entered into in the past), but in the end it's just hype on the part of GR (insinuating that more dilution might not be necessary), and a clever way for Lincoln to make a dime (instead of buying, and sitting on HUGE risk for 5-10 years).